[{"id":"b7d5c857-2d6d-49ee-a382-780def97434a","acronym":"SOHO-01","url":"https://clinicaltrials.gov/study/NCT05099172","created_at":"2021-10-29T14:53:14.073Z","updated_at":"2025-02-25T15:35:22.229Z","phase":"Phase 1/2","brief_title":"First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)","source_id_and_acronym":"NCT05099172 - SOHO-01","lead_sponsor":"Bayer","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hyrnuo (sevabertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 370","initiation":"Initiation: 10/25/2021","start_date":" 10/25/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-11"}]